Ventyx Biosciences (VTYX) Competitors $2.63 -0.17 (-6.07%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.75 +0.12 (+4.52%) As of 08/1/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTYX vs. NRIX, QURE, SNDX, TRVI, MENS, NAGE, XERS, NUVB, MAZE, and CRONShould you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include Nurix Therapeutics (NRIX), uniQure (QURE), Syndax Pharmaceuticals (SNDX), Trevi Therapeutics (TRVI), Jyong Biotech (MENS), Niagen Bioscience (NAGE), Xeris Biopharma (XERS), Nuvation Bio (NUVB), Maze Therapeutics (MAZE), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Ventyx Biosciences vs. Its Competitors Nurix Therapeutics uniQure Syndax Pharmaceuticals Trevi Therapeutics Jyong Biotech Niagen Bioscience Xeris Biopharma Nuvation Bio Maze Therapeutics Cronos Group Ventyx Biosciences (NASDAQ:VTYX) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations. Which has more volatility & risk, VTYX or NRIX? Ventyx Biosciences has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Which has stronger earnings and valuation, VTYX or NRIX? Ventyx Biosciences has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVentyx BiosciencesN/AN/A-$135.12M-$1.75-1.50Nurix Therapeutics$54.55M15.47-$193.57M-$2.61-4.23 Does the media prefer VTYX or NRIX? In the previous week, Nurix Therapeutics had 12 more articles in the media than Ventyx Biosciences. MarketBeat recorded 15 mentions for Nurix Therapeutics and 3 mentions for Ventyx Biosciences. Ventyx Biosciences' average media sentiment score of 0.94 beat Nurix Therapeutics' score of 0.69 indicating that Ventyx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ventyx Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in VTYX or NRIX? 97.9% of Ventyx Biosciences shares are held by institutional investors. 14.5% of Ventyx Biosciences shares are held by insiders. Comparatively, 7.4% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is VTYX or NRIX more profitable? Ventyx Biosciences has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -234.57%. Nurix Therapeutics' return on equity of -45.26% beat Ventyx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ventyx BiosciencesN/A -47.45% -43.49% Nurix Therapeutics -234.57%-45.26%-34.71% Do analysts prefer VTYX or NRIX? Ventyx Biosciences presently has a consensus price target of $10.00, suggesting a potential upside of 280.23%. Nurix Therapeutics has a consensus price target of $28.87, suggesting a potential upside of 161.47%. Given Ventyx Biosciences' higher probable upside, equities analysts clearly believe Ventyx Biosciences is more favorable than Nurix Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.81 SummaryVentyx Biosciences beats Nurix Therapeutics on 8 of the 15 factors compared between the two stocks. Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTYX vs. The Competition Export to ExcelMetricVentyx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$199.25M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-1.5017.6228.6723.80Price / SalesN/A179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book0.738.508.275.55Net Income-$135.12M-$55.06M$3.24B$259.03M7 Day Performance-17.30%-3.98%-3.69%-4.59%1 Month Performance30.20%9.59%4.33%4.46%1 Year Performance26.44%6.72%25.95%18.03% Ventyx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTYXVentyx Biosciences2.9124 of 5 stars$2.63-6.1%$10.00+280.2%+17.4%$199.25MN/A-1.5030News CoverageShort Interest ↑NRIXNurix Therapeutics2.5151 of 5 stars$11.25+0.4%$29.31+160.6%-48.6%$857M$54.55M-4.31300News CoverageAnalyst ForecastQUREuniQure2.4186 of 5 stars$14.50-3.3%$37.82+160.8%+83.0%$821.09M$27.12M-3.30500Trending NewsEarnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionSNDXSyndax Pharmaceuticals3.5579 of 5 stars$9.73+2.9%$34.10+250.5%-54.6%$814.01M$23.68M-2.52110Upcoming EarningsTRVITrevi Therapeutics2.4543 of 5 stars$6.82-0.6%$20.88+206.1%+136.5%$804.63MN/A-15.1620News CoverageUpcoming EarningsShort Interest ↑MENSJyong BiotechN/A$11.00+4.3%N/AN/A$802.09MN/A0.0031Positive NewsQuiet Period ExpirationNAGENiagen Bioscience1.0385 of 5 stars$9.68-4.7%$13.22+36.6%N/A$800.69M$99.60M56.94120Analyst DowngradeXERSXeris Biopharma3.383 of 5 stars$5.14+0.6%$6.25+21.6%+121.4%$799.12M$203.07M-17.13290News CoveragePositive NewsUpcoming EarningsShort Interest ↑NUVBNuvation Bio2.2856 of 5 stars$2.36+2.4%$7.17+204.3%-37.4%$782.60M$7.87M-1.0060News CoverageUpcoming EarningsMAZEMaze TherapeuticsN/A$16.66-6.3%$23.50+41.1%N/A$778.71M$167.50M0.00121Lockup ExpirationGap UpHigh Trading VolumeCRONCronos Group2.3244 of 5 stars$2.09+4.0%N/A-17.0%$775.22M$117.61M16.08450Upcoming Earnings Related Companies and Tools Related Companies Nurix Therapeutics Competitors uniQure Competitors Syndax Pharmaceuticals Competitors Trevi Therapeutics Competitors Jyong Biotech Competitors Niagen Bioscience Competitors Xeris Biopharma Competitors Nuvation Bio Competitors Maze Therapeutics Competitors Cronos Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTYX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VTYX Stock Alerts